TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide
February 24th, 2009
The Microbicide Trials Network, a worldwide collaborative group funded by the US National Institutes of Health, has released final results from its Phase II/IIb safety and effectiveness study of two microbicides, BufferGel and PRO2000 (0.5 percent concentration), both vaginal gels being tested to prevent HIV transmission to women during sex. BufferGel's primary action is to lower vaginal pH while PRO2000 is a large charged polymer designed to interfere with HIV's interactions with its target cells. Results from the four-year trial (HPTN 035), conducted in Malawi, South Africa, the United States, Zambia and Zimbabwe, show that both products are safe as tested. Quite...
Source: TB & Outbreaks Week (2009-02-24)
|
